Late-Recurrence in Clinical Utility

Late recurrence risk

ASCO® guidelines recommend 10 years of hormonal therapy for ER-positive breast cancer based on the aTTom and ATLAS studies.2,3 The challenge facing physicians is identifying which patients are at higher risk of distant recurrence after five years of hormone therapy.

The Breast Recurrence Score test may identify patients who are at higher risk of distant recurrence beyond five years and might have greater benefit from extended hormonal therapy.4

  • The association between quantitative ER and tamoxifen benefit has been shown in the landmark NSABP B-14 study.1
  • The Recurrence Score result was significantly associated with prediction of late distant recurrence (years 5-15) in patients with higher quantitative ER expression (>9.1).4


  1. Kim et al. J Clin Oncol. 2011.
  2. Davies et al. Lancet. 2013.
  3. Al-Mubarak et al. PLoS One. 2014.
  4. Wolmark et al. J Clin Oncol. 2016.

a. DOI: 10.1056/NEJMoa1804710.

*American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy

Making cancer care smarter.®